Barinthus Biotherapeutics plc (BRNS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.74 (-2.49%), Market cap $0.03B, 52-week low–high $0.54 ~ $1.97.
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Insti
Financial statements, price targets, institutional (13F) holdings and related news for Barinthus Biotherapeutics plc are updated in real time on BlackAll Trade.
Barinthus Biotherapeutics plc trades at $0.74 (-2.49%). Real-time quotes and charts are available on BlackAll Trade.
Barinthus Biotherapeutics plc has a market cap of about $0.03B.
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom.